Concept Life Sciences Group Offers Unrivalled Expertise as a Strategic Partner
News May 04, 2016
Under two years ago the Concept Life Sciences Group was created following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited and Resource & Environmental Consultants Limited. Following two further acquisitions during 2015 (CXR Biosciences and Agenda1) Concept Life Sciences is now an integrated group offering a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries. Testament to the truly collaborative services the Group now offers, Concept Life Sciences has recently undergone a rebranding exercise that more clearly identifies each of the respective companies as part of the Concept Life Sciences group.
Discussing the project Michael Fort, Chairman said: “Our rebranding exercise was much more than the development of a new look and feel for the business and has been designed to truly reflect the integrated solutions we can now offer. We have undergone a rigorous business review which has enabled us to maintain the best of each of the companies we have acquired whilst adding further value to our clients by genuinely understanding where the synergies lie. Our clients will continue to access the specific services for which the individual brands are well known for and also access a broader range of solutions with one point of contact.”
With companies across a number of sectors facing challenges to achieve and maintain profitable growth, outsourcing remains a significant opportunity. By forming strategic relationships with partners such as Concept Life Sciences, companies can both spread commercial risk and focus on their core competencies whilst accessing specialised expertise and benefitting from the resulting cost and time to market advantages.
Michael Fort continued: “The way we have structured our business enables us to provide project support as efficiently as end-to-end support to our clients. We can work with specific functional areas or work alongside a client from first concept through to the clinic door.”
Over 70 per cent of the Concept Life Sciences team who work in the Discovery & Development division are PhD scientists experienced in complex chemistry, pharmacology and pathways analysis working alongside their biology colleagues who are experts in investigative and mechanistic toxicology, exploratory and discovery toxicology, PK and metabolic and dermal absorption. By ensuring Concept Life Science’s scientific teams work in step with each other, clients are well placed to benefit from an accelerated testing cycle.
Additionally, through their analytics division, Concept Life Sciences offers over 35 different analytical techniques including specialist characterisation instrumentation, chromatography and formulation/salt/polymorph screening to complete the Design, Make, Test cycle.
A significant part of the Group offers consultancy and scientific analytical services to the life sciences, food and environmental sectors. The division carries out a wide range of routine testing and specialist analysis, developing new methodologies to deliver and support scientific solutions. Services include food chemistry, nutrition, pesticide and allergen testing for the food sector and contaminated land, bio analysis in occupational health, waters, air and waste for the environmental market. The service offering has recently been expanded to include pharmaceutical microbiology services, stability storage and other services specifically designed to support the life sciences markets. The consultancy service operates from multiple locations throughout the UK and provides services and solutions to challenges in acoustics, air quality, asbestos, ecology and geo-environmental issues.
Michael Fort concluded: “The rationale for the creation of the Concept Life Sciences Group was the recognition that there is a need in the market for a services organisation that has a proven track record in discovery science, problem solving and collaboration. We have built an organisation that delivers one of the widest range of analytical services available in Europe.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE